Doenças neurodegenerativas e canabinoides: revisão narrativa
DOI:
https://doi.org/10.34024/rnc.2023.v31.14952Palavras-chave:
Doenças neurodegenerativas, Neuroinflamação, Canabidinoides, CanabidiolResumo
Introdução. As doenças neurodegenerativas afetam grande parte da população no mundo, principalmente idosos. Essas patologias interrompem a função motora e cognitiva, a homeostase dos pacientes, impactando na qualidade de vida. As terapias atuais para os distúrbios neurodegenerativos têm a finalidade de aliviar os sintomas e à medida que a doença progride, a eficácia dos tratamentos farmacológicos é reduzida. Objetivo. Descrever sobre as principais doenças neurodegenerativas e a utilização do canabinoides como alternativa no tratamento destas patologias. Método. Estudo de revisão narrativa que mostra as principais doenças neurodegenerativas e a utilização dos canabinoides para o tratamento de doenças neurodegenerativas. Resultados. Os estudos mostraram que os derivados da Cannabis sativa apresentam potencial terapêutico para o tratamento das doenças neurodegenerativas devido as suas propriedade anti-inflamatórias, antioxidantes e neuroprotetoras. Os principais compostos, o canabidiol (CBD) e Tetrahidrocanabinol (THC) apresentam importante papel na neuromodulação no sistema nervoso central degenerado, minimizando os danos causados pelas doenças neurodegenerativas. Conclusões. Apesar da literatura apontar o potencial terapêutico dos canabinoides, ainda há incertezas sobre a qualidade dos produtos e as doses consideradas ativas, bem como de interações medicamentosas.
Métricas
Referências
Erkkinen MG, Kim M-O, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol 2018;10:a033118. https://doi.org/10.1101/cshperspect.a033118
De Marchi F, Contaldi E, Magistrelli L, Cantello R, Comi C, Mazzini L. Telehealth in Neurodegenerative Diseases: Opportunities and Challenges for Patients and Physicians. Brain Sci 2021;11:237. https://doi.org/10.3390/brainsci11020237
Guedes da Paz E, De Jesus da Silva Mendes D, Nogueira Brito S, Oliveira Barbosa W. Doenças neurodegenerativas em adultos e idosos: um estudo epidemiológico descritivo. Rev Neurocienc 2021;29:1–11. https://doi.org/10.34024/rnc.2021.v29.12348
Chi H, Chang H-Y, Sang T-K. Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases. Int J Mol Sci 2018;19:3082. https://doi.org/10.3390/ijms19103082
Mudò G, Frinchi M, Nuzzo D, Scaduto P, Plescia F, Massenti MF, et al. Anti-inflammatory and cognitive effects of interferon-β1a (IFNβ1a) in a rat model of Alzheimer’s disease. J Neuroinflammation 2019;16:44. https://doi.org/10.1186/s12974-019-1417-4
Ghosh A, Birngruber T, Sattler W, Kroath T, Ratzer M, Sinner F, et al. Assessment of blood-brain barrier function and the neuroinflammatory response in the rat brain by using cerebral open flow microperfusion (cOFM). PLoS One 2014;9:e98143. https://doi.org/10.1371/journal.pone.0098143
Liu Y, Zhang Y, Zheng X, Fang T, Yang X, Luo X, et al. Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice. J Neuroinflamm 2018;15:112. https://doi.org/10.1186/s12974-018-1141-5
Barichello T, Fortunato JJ, Vitali ÂM, Feier G, Reinke A, Moreira JCF, et al. Oxidative variables in the rat brain after sepsis induced by cecal ligation and perforation. Crit Care Med 2006;34:886-9. https://doi.org/10.1097/01.CCM.0000201880.50116.12
Feng Y-S, Tan Z-X, Wu L-Y, Dong F, Zhang F. The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases. Biomed Pharmacother 2021;138:111428. https://doi.org/10.1016/j.biopha.2021.111428
Sudhakar V, Richardson RM. Gene Therapy for Neurodegenerative Diseases. Neurotherapeutics 2019;16:166-75. https://doi.org/10.1007/s13311-018-00694-0
Gurgel HLC, Lucena GGC, De Faria MD, De Azevedo Maia GL. Therapeutic use of cannabidiol: The lawsuit in the state of pernambuco, Brazil. Saude Soc 2019;28:283-95. https://doi.org/10.1590/S0104-12902019180812
Bitencourt RM, Takahashi RN. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: From bench research to confirmation in human trials. Front Neurosci 2018;12:1-10. https://doi.org/10.3389/fnins.2018.00502
Ligresti A, De Petrocellis L, Di Marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiol Rev 2016;96:1593-659. https://doi.org/10.1152/physrev.00002.2016
Campos AC, Fogaça M V, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res 2016;112:119-27. https://doi.org/10.1016/j.phrs.2016.01.033
Carvalho CR, Franco PLC, Eidt I, Hoeller AA, Walz R. Canabinoides e Epilepsia: potencial terapêutico do canabidiol. VITTALLE Rev Cienc Saúde 2017;29:54-63. https://doi.org/10.14295/vittalle.v29i1.6292
Malcher-Lopes R. Canabinoides ajudam a desvendar aspectos etiológicos em comum e trazem esperança para o tratamento de autismo e epilepsia. Rev Biol 2014;13:43-59. https://doi.org/10.7594/revbio.13.01.07
Matos RLA, Spinola LA, Barboza LL, Garcia DR, França TCC, Affonsoa RS. O uso do canabidiol no tratamento da epilepsia. Rev Virtual Quim 2017;9:786-814. http://doi.org/10.21577/1984-6835.20170049
Gulbenkian Descobrir; Fundação Calouste. Ciência em Cena O cérebro e as doenças neurodegenerativas. 2020; 30p. https://content.gulbenkian.pt/wp-content/uploads/sites/16/2018/04/24100926/Dossie_2015_Neurodegenerativas.pdf
Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011;7:137-52. https://doi.org/10.1038/nrneurol.2011.2
Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:137-52. https://doi.org/10.1101/cshperspect.a006239
Kovacs G. Molecular pathology of neurodegenerative diseases: principles and practice. J Clin Pathol 2019;72:725-35. https://doi.org/10.1136/jclinpath-2019-205952
Markowitsch HJ, Staniloiu A. Amnesic disorders. Lancet 2012;380:1429-40. https://doi.org/10.1016/S0140-6736(11)61304-4
Mattos EBT, Kovácsb MJ. Alzheimer’s disease: The unique experience of family caregivers. Psicol USP 2020;31:1-11. https://doi.org/10.1590/0103-6564e180023
Cabreira V, Massano J. Doença de Parkinson: Revisão Clínica e Atualização. Acta Med Port 2019;32:661. https://doi.org/10.20344/amp.11978
Silva AS, Bromochenkel C. Esclerose Lateral Amiotrófica : Manifestações Psicológicas do Enlutar-se. Rev Lat-Am Psicol Corporal 2019;6:89-108. https://psicorporal.emnuvens.com.br/rlapc/article/view/62
Silva VM, Silva DF. Esclerose Múltipla: imunopatologia, diagnóstico e tratamento – Artigo de revisão. Interfaces Cient Saúde Ambient 2014;2:81-90. https://doi.org/10.17564/2316-3798.2014v2n3p81-90
Oliveira CR, Mendes Á, Sousa L. Health promotion in families with paramyloidosis: The role of elders with younger family members. Cad Saude Publica 2017;33:1-12. https://doi.org/10.1590/0102-311X00185515
Kovacs GG. Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci 2016;17:189. https://doi.org/10.3390/ijms17020189
Brettschneider J, Tredici K Del, Lee VMY, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 2015;16:109-20. https://doi.org/10.1038/nrn3887
Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 2011;134:2595-609. https://doi.org/10.1093/brain/awr201
von Bernhardi R, Eugenín J. Alzheimer’s disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal 2012;16:974-1031. https://doi.org/10.1089/ars.2011.4082
Nijholt DAT, De Kimpe L, Elfrink HL, Hoozemans JJM, Scheper W. Removing protein aggregates: the role of proteolysis in neurodegeneration. Curr Med Chem 2011;18:2459-76. https://doi.org/10.2174/092986711795843236
Eisele YS, Duyckaerts C. Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 2016;131:5-25. https://doi.org/10.1007/s00401-015-1516-y
Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci 2016;17:251-60. https://doi.org/10.1038/nrn.2016.13
Lu H-C, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry 2016;79:516-25. https://doi.org/10.1016/j.biopsych.2015.07.028
Garcia A, Soria-Gomez E, Bellocchio L, Marsicano G. Cannabinoid receptor type-1: breaking the dogmas. F1000Res 2016;5:F1000. https://doi.org/10.12688/f1000research.8245.1
Costa JLGP, Maia LO, Orlandi-Mattos P, Villares JC, Fernandez Esteves MA. Neurobiology of Cannabis: From the endocannabinoid system to cannabis-related disorders. J Bras Psiquiatr 2011;60:111-22. https://doi.org/10.1590/S0047-20852011000200006
Saito VM, Wotjak CT, Moreira FA. Exploração farmacológica do sistema endocanablnolde: Novas perspectivas para o tratamento de transtornos de ansiedade e depressão? Rev Bras Psiquiatr 2010;32(SUPPL 1):7-14. https://doi.org/10.1590/S1516-44462010000500004
Soares VP, Campos AC. Evidences for the Anti-panic Actions of Cannabidiol. Curr Neuropharmacol 2017;15:291-9. https://doi.org/10.2174/1570159x14666160509123955
Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012;367:3364-78. https://doi.org/10.1098/rstb.2011.0389
Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules 2019;24:1459. https://doi.org/10.3390/molecules24081459
Ibeas Bih C, Chen T, Nunn AVW, Bazelot M, Dallas M, Whalley BJ. Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics 2015;12:699-730. https://doi.org/10.1007/s13311-015-0377-3
Soares RZ, Vuolo F, Dall’Igna DM, Michels M, Crippa JAS, Hallak JEC, et al. Evaluation of the role of the cannabidiol system in an animal model of ischemia/reperfusion kidney injury. Rev Bras Ter intensiva 2015;27:383-9. https://doi.org/10.5935/0103-507X.20150064
González-García C, Torres IM, García-Hernández R, Campos-Ruíz L, Esparragoza LR, Coronado MJ, et al. Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis. Exp Neurol 2017;298:57-67. https://doi.org/10.1016/j.expneurol.2017.08.017
Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiol Dis 2010;37:434-40. https://doi.org/10.1016/j.nbd.2009.10.023
Jean-Gilles L, Gran B, Constantinescu CS. Interaction between cytokines, cannabinoids and the nervous system. Immunobiology 2010;215:606-10. https://doi.org/10.1016/j.imbio.2009.12.006
Rajan TS, Giacoppo S, Iori R, De Nicola GR, Grassi G, Pollastro F, et al. Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. Fitoterapia 2016;112:104-15. https://doi.org/10.1016/j.fitote.2016.05.008
Catterall WA. Forty Years of Sodium Channels: Structure, Function, Pharmacology, and Epilepsy. Neurochem Res 2017;42:2495-504. https://doi.org/10.1007/s11064-017-2314-9
Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-κB involvement. Neurosci Lett 2006;399:91-5. https://doi.org/10.1016/j.neulet.2006.01.047
Cooray R, Gupta V, Suphioglu C. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review. Mol Neurobiol 2020;57:4878-90. https://doi.org/10.1007/s12035-020-02054-6
Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S. Endocannabinoid system in neurodegenerative disorders. J Neurochem 2017;142:624-48. https://doi.org/10.1111/jnc.14098
Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology 2022;107:131-49. https://doi.org/10.1159/000521683
Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. Int J Mol Sci 2022; 23:3344. https://doi.org/10.3390/ijms23063344
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2023 Cyntia Michielin Lopes, Rick Wilhiam de Camargo, Rafael Mariano Bitencourt
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
